Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Kyverna Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 88
- −5 vs. Q3 2024
- Shares held
- 28.9M
- +3.98M (+16.0%) vs. Q3 2024
- Total value
- $108.0M
- −$14.4M (−11.8%) vs. Q3 2024
- New holders
- 23
- 32 more added
- Sold out
- 28
- 14 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 120 | $335.1M |
| Q1 2026 | 111 | $300.5M |
| Q4 2025 | 99 | $320.8M |
| Q3 2025 | 75 | $136.1M |
| Q2 2025 | 79 | $71.2M |
| Q1 2025 | 87 | $49.8M |
| Q4 2024 | 88 | $108.0M |
| Q3 2024 | 94 | $138.3M |
| Q2 2024 | 88 | $239.7M |
| Q1 2024 | 90 | $762.3M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Kyverna Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −33,308−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −27,580−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −26,195−100.0% | Sold out |
| Discovery Capital Management, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −22,900−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −11,028−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −10,179−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −6,381−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −968−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −314−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −182−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −122−100.0% | Sold out |
| Washington Trust Advisors, Inc. | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Northpond Ventures, LLC | – | – | – | – | Not filed |